News for Neuren Pharmaceuticals Limited (NURPF)

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the fourth quarter and full year ended December 31, 2024. ”œWe closed 2

ACADIA Pharmaceuticals Inc (ACAD) has announced the successful closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million,

ACADIA Pharmaceuticals has a promising pipeline of drug candidates, including ACP-101 for Prader-Willi syndrome. Read why ACAD stock is a Buy.

Neuren Phase 2 trial shows significant improvements in Pitt Hopkins syndrome

In this article, we will be taking a look at the 20 biggest health care companies in Australia, 2024.

ASX 200 poised for a lift amid mixed global market signals

S&P/ASX 200 Index gains 1.1%, while four ASX shares face downturn

The FDA has greenlighted Daybue, a treatment developed by Acadia Pharmaceuticals (ACAD) for rare neurodevelopmental disorder Rett syndrome. Read the full story here.

-- First and only approved therapy for Rett syndrome, a rare, neurodevelopmental disorder, which affects 6,000 to 9,000 patients in the U.S.1 -- Company expects DAYBUE to be available by the end of... | March 11, 2023

The ASX health sector is down more than 8% as 2022 comes to end but in signs of optimism for 2023, Morgans has a basket of stocks to watch.

-- NDA granted priority review -- Prescription Drug User Fee Act action date set for March 12, 2023 ... | September 12, 2022